1 month on SS 31 - next time I’m feeling flush I’ll splurge on this one again.
Ongoing with ARA 290, will go for 3 months and see,
My litmus test will be our daughter who had a sever allergic reaction to Cipro is what they call “floxed” one of her symptom for the past 8 years is neuropathy from the knees down that ebbs and flows but the pins and needles are there all the time.
She is 2 weeks in now and no result, it seems like it takes 28+ days for any result.
I’ve been making a skin care product with GHK-cu for about 3 years. Mostly for friends and family, works well.
Four months ago I was getting a dry spot on the right side of my forehead and even my blue magic was not fixing it.
I started the GLOW protocol 4 weeks ago, which is a BPC+TB500+GHK-cu combo that is popular with the influencers. I’ve been taking BPC+TB for over 2 years now and it’s been great with fast recovery, healed all my old war wounds, etc. But was not doing anything for the dry spot.
After 2 weeks of GLOW I was thinking it was helping. Now a month in and the dry spot is gone. I’m sold on GLOW
The commonly sold version is 10-10-50 10mg BPC + 10mg TB + 50mg GHK
My combo is 15+15+60
If I was only a casual user the 10-10-50 might be acceptable but the 10-10 dose is lower than I currently use daily. So I jacked it up,
Every morning I get 500mcg + 500mcg + 2.0mg
If I was to use the “standard” GLOW every day I would only get
335mcg + 335mcg + 1.67mg
People often experience “sting” from GHK-cu and dilute it quite a bit. Since I only use iPEN cartridges now and they are limited to 3mL BAC water vs typical vials that hold 5mL My dilution rate is quite a bit lower. So to prevent sting I use 1mL PBS and 2ml BAC water and it works a treat
I’ve also switched my “type” of TB500 from the frag 1-4 to the full Thymosin β4 43aa, while it is a bit more expensive I’ve been doing a lot of research with Perplexity on various peptides and this change makes sense to me.
An intrepid self-researcher on another forum discovered that diluting GHK-Cu with even a small amount of GHK-basic completely gets rid of the sting and the injection site reaction, for those who have access to GHK-basic. The theory is that free copper in the GHK-Cu is responsible for the reaction and that the small amount of GHK-basic binds it up.
Hi Steve, where are you buying your peptides? I just finished a round of tb4 from my doc but it was expensive. Looking to try bp157 next and would like to find a reliable online source. They have both helped in healing an injury I had in the past. Thanks in advance.
I was recommended TB4 to help with recovery s/p arthroscopic knee surgery with some cartilage damage. Unfortunately, I can’t find the basis for this recommendation. Studies on arthritis and TB4 show that it is elevated and proportionate to the degree of OA both in the joint and in serum. Elevated TB4 seems to be a marker for OA severity. Also, MOA doesn’t make sense in regards to OA. It activates MMPs which breakdown cartilage, so again I see no possible benefit for my case and potential worsening. You can argue it is elevated as a body healing response to cartilage damage, but if that’s true the body is already overproducing it and I shouldn’t need to supplement. More likely, it seems to be detrimental to joint health from what I can find. Thoughts or experiences from anyone?
I cannot wait to try this! Results and conclusion: The effective dose of GB-115 was determined at 6 mg per day. Drug action is characterized by fast onset of anxiolytic effect with stimulating properties and beneficial effect on sleep disturbances and autonomic symptoms. GB-115 treatment was associated with favorable changes in attention parameters, reaction time and overall performance. In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances. GB-115 is safe and has a good tolerability.
GPT5 summary of full study: Study Title: Results of a Clinical Study of a New Anxiolytic, a Blocker of Central Cholecystokinin Receptors (GB-115) Published in: S.S. Korsakov Journal of Neurology and Psychiatry, 2019, vol. 119, no. 8, pp. 53–60. Authors: Neznamov G.G., Dorofeeva O.A., Metlina M.V., Syunyakov T.S., Minaev S.V., Ivashkina N.Yu., Martyanov V.A., Seredenin S.B.
Objective
To evaluate the anxiolytic (anti-anxiety) action, safety, and tolerability of GB-115, a low-affinity central cholecystokinin (CCK) receptor blocker, in patients with generalized anxiety disorder (GAD).
Background
CCK plays a regulatory role in anxiety and interacts with neurotransmitters like GABA, dopamine, and endogenous opioids.
GB-115 (amide N-(6-phenylhexanoyl)-glycyl-L-tryptophan) is a novel peptide compound synthesized at the Zakusov Institute.
Preclinical studies showed anxiolytic effects without sedation, muscle relaxation, or dependence potential—unlike benzodiazepines.
GB-115 also showed no mutagenic, embryotoxic, or allergenic properties.
Methods
Design: Open-label pilot Phase IIa clinical study.
Sample: 31 patients (22 women, 9 men), aged 22–53 years, diagnosed with GAD (ICD-10 F41.1).
Duration: 21 days.
Dosing: Sequential escalation from 3 mg to 12 mg daily to determine an effective dose.
Final effective dose:6 mg/day.
Assessments:
Hamilton Anxiety Rating Scale (HAM-A)
Spilberger–Khanin State Anxiety Test
Multidimensional Fatigue Inventory (MFI)
Clinical Global Impression (CGI)
NS-Psychotest (computerized cognitive testing)
Symptom severity and sleep quality evaluations.
Results
1. Dose finding
3 mg/day: mild effects; insufficient efficacy.
6 mg/day: strong and consistent therapeutic effect.
2. Efficacy
Anxiolytic effect: Anxiety scores on HAM-A decreased from 22.2 to 6.3 by day 21 (p<0.01).
Fatigue reduction: MFI decreased from 64.3 to 36.0 (p<0.01).
Sleep improvement: Reduction in insomnia and nocturnal awakenings.
Cognitive and psychomotor enhancement: Faster reaction times, improved attention and operator performance (via NS-Psychotest).
Clinical Global Impression (CGI):
By day 21, 92% of patients experienced significant or very significant improvement.
Effect onset occurred rapidly, within 3–7 days.
3. Safety and tolerability
Excellent overall tolerability.
Adverse events in 4 of 31 patients (12.9%), all mild and transient: mild hypertension, dry mouth, hypercholesterolemia, menstrual irregularity.
No sedation, motor impairment, or withdrawal phenomena observed.
Mechanistic implication: Supports the role of the cholecystokinin system in anxiety regulation.
Comparison to SSRIs/SNRIs: GB-115 lacks the early-phase overstimulation and anxiety exacerbation typical of antidepressants.
Conclusion
GB-115 is a novel, fast-acting anxiolytic that combines anti-anxiety and mild activating properties without sedation or dependence risk. It demonstrated high tolerability and safety, suggesting potential as a next-generation treatment for generalized anxiety disorder and anxiety-asthenic syndromes. Further controlled trials are recommended to confirm its efficacy and register it as a therapeutic agent.
Citation:
Neznamov G.G., Dorofeeva O.A., Metlina M.V., Syunyakov T.S., Minaev S.V., Ivashkina N.Yu., Martyanov V.A., Seredenin S.B. Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(8):53–60.